Announcements
- Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy
- Oculis kynnir jákvæðar niðurstöður úr fasa 2b RELIEF-rannsókn með Licaminlimab, hannað til að umbylta meðferð augnþurrks með nákvæmnislyfjameðferð
- Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
- Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
- Oculis birtir niðurstöður aðalfundar 2024 og tilkynnir um skipanir í stjórn og vísindaráð
- Oculis updates share capital for its existing at-the-market offering program
- Oculis Reports Q1 2024 Financial Results and Provides Company Updates
- Oculis Publishes Invitation to the Annual General Meeting
- Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
More ▼
Key statistics
On Monday, Oculis Holding AG (OCS:ICX) closed at 1,640.00, 1.86% above its 52-week low of 1,610.00, set on May 31, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1,700.00 |
---|---|
High | 1,720.00 |
Low | 1,640.00 |
Bid | 1,640.00 |
Offer | 1,640.00 |
Previous close | 1,660.00 |
Average volume | 38.45k |
---|---|
Shares outstanding | 46.44m |
Free float | 43.43m |
P/E (TTM) | -- |
Market cap | 557.62m USD |
EPS (TTM) | -1.85 USD |
Data delayed at least 15 minutes, as of Jun 10 2024 17:00 BST.
More ▼